-
161
Matching plus regression adjustment for the estimation of the average treatment effect on survival outcomes: a case study with mosunetuzumab in relapsed/refractory follicular lymph...
Published 2025-02-01“…Abstract Background and objectives The National Institute for Health and Care Excellence (England’s health technology assessment body) recommend the use of the average treatment effect (ATE) as an estimand for economic evaluations. …”
Get full text
Article -
162
-
163
-
164
-
165
-
166
-
167
Interventions for Type 2 Diabetes Prevention and Management Among Indigenous Children and Youth: A Systematic Review
Published 2025-01-01“…An adapted version of the National Institute of Health (NIH) quality assessment tool for pre‐post intervention studies was used for quality assessment. …”
Get full text
Article -
168
Clinical Evidence in the Treatment of Obstructive Sleep Apnoea with Oral Appliances: A Systematic Review
Published 2021-01-01Get full text
Article -
169
Association of Asthma Control and Metered-Dose Inhaler Use Technique among Adult Asthmatic Patients Attending Outpatient Clinic, in Resource-Limited Country: A Prospective Study
Published 2019-01-01“…Inhalation technique was obtained using a standard checklist of steps recommended in National Institute of Health (NIH) guidelines. Patient adherence using asthma inhalation test and asthma control status was assessed by 2017 GINA guideline. …”
Get full text
Article -
170
Stem Cell–Based Therapies via Different Administration Route for Stroke: A Meta-analysis of Comparative Studies
Published 2025-02-01“…Primary outcomes included the National Institute of Health Stroke Scale (NIHSS), Barthel Index (BI), and modified Rankin Scale (mRS), while secondary outcomes included mortality and adverse events. …”
Get full text
Article -
171
-
172
-
173
-
174
Experiences of ‘traditional’ and ‘one-stop’ MRI-based prostate cancer diagnostic pathways in England: a qualitative study with patients and GPs
Published 2022-07-01“…Objectives This study aimed to understand and explore patient and general practitioner (GP) experiences of ‘traditional’ and ‘one-stop’ prostate cancer diagnostic pathways in England.Design Qualitative study using semi-structured interviews, analysed using inductive thematic analysisSetting Patients were recruited from National Health Service (NHS) Trusts in London and in Devon; GPs were recruited via National Institute for Health Research (NIHR) Clinical Research Networks. …”
Get full text
Article -
175
The Cost-effectiveness of Celecoxib versus Non-steroidal Anti-inflammatory Drugs plus Proton-pump Inhibitors for Treating Osteoarthritis in Algeria
Published 2013-10-01“…**Methods:** The National Institute for Health and Clinical Excellence (NICE) health economic model from UK, updated with relative risks of adverse events using CONDOR trial data, was adapted for costeffectiveness analysis in OA patients aged ≥65 years. …”
Get full text
Article -
176
-
177
Health-Related Quality-of-Life Utility Values in Adults With Late-Onset Pompe Disease: Analyses of EQ-5D Data From the PROPEL Clinical Trial
Published 2024-09-01“…EQ-5D-5L utility values were mapped to EQ-5D-3L values using the van Hout algorithm as recommended by the EuroQoL and the National Institute of Health and Care Excellence position statement at time of analysis. …”
Get full text
Article -
178
Comparison of glycosylated fibronectin versus soluble fms-like tyrosine kinase/placental growth factor ratio testing for the assessment of pre-eclampsia: protocol for a multicentre...
Published 2025-02-01“…The prediction of pre-eclampsia in high-risk populations using angiogenic markers, such as serum placental growth factor (PlGF) assessment, has been shown to improve maternal outcomes and is recommended by the National Institute for Health and Care Excellence (NICE). However, such tests are not yet available at the point of care (POC). …”
Get full text
Article -
179
-
180
UK multiple sclerosis risk-sharing scheme: a new natural history dataset and an improved Markov model
Published 2014-01-01“…Objectives In 2002, the UK's National Institute for Health and Care Excellence concluded that the multiple sclerosis (MS) disease modifying therapies; interferon-β and glatiramer acetate, were not cost effective over the short term but recognised that reducing disability over the longer term might dramatically improve the cost effectiveness. …”
Get full text
Article